Regeneus Ltd (ASX:RGS) is a Sydney-based clinical-stage regenerative medicine company using stem cell technologies to develop a portfolio of novel cell-based therapies. The regenerative therapies seek to address unmet medical needs in human health markets, focusing on neuropathic pain, including osteoarthritis and various skin conditions, with its platform technologies Progenza(TM) and Sygenus. Visit www.regeneus.com.au for more information.
Regenerative medicine company Regeneus Ltd (ASX:RGS) wishes to officially respond to the ABC 7.30's Sell Therapy story, which aired on 6th October 2014.
Regeneus Ltd (ASX:RGS) is pleased to announce it has received $3.7m from the Australian Government's Research and Development Tax Incentive Program for activities conducted during the 2014 financial year.
Regenerative medicine company, Regeneus Ltd (ASX:RGS), today announced plans to open the HiQCell Regenerative Medicine Clinic in Singapore, and the appointment of leading specialist sports physician, Dr Patrick Goh, as Medical Director.
Regenerative medicine company, Regeneus (ASX:RGS) today announced that it had officially launched its Kvax canine cancer treatment within the Australian veterinary market.
Regeneus Ltd (ASX:RGS) is pleased to announce that it has successfully achieved its target of raising A$3m through its Share Purchase Plan offered to shareholders. This now completes the second part of the company's A$6m raising announced to the market on 8 August 2014.
Regeneus Ltd (ASX:RGS) announced today that the Australian Football League (AFL) has granted caseby-case approval for the use of its innovative stem cell therapy, HiQCell(R) as a treatment option for injured AFL players, typically including impact related osteoarthritis and tendonitis.
Appendix 4G and Corporate Governance Statement
Appendix 3Z - Final Director's Interest Notice
Appendix 4D and Half-Year Report
